Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Shares of Novavax Inc. NVAX slid 1.51% to $10.08 Monday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to 22,374.18 ...

Novavax swings to profit in Q4 CEO remains optimistic despite U.S. regulatory uncertainties Shares surge over 22% after strong results Feb 26 (Reuters) - Novavax (NVAX.O), opens new tab raised its ...

The MarketWatch News Department was not involved in the creation of this content. -- Non-exclusive license allows for development by Pfizer to utilize Matrix-M(R) for up to two disease areas with its ...

Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...